Back to search
FDAFDA · Food and drugs·Recall number D-0437-2024

Rifampin Capsules USP, 300mg, 30-count bottles, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202, Manufactured by: Lupin Limited Aurangabad 431 210 India, NDC 6818-0659-06

Published April 17, 2024 · Recall initiated: March 21, 2024

Summary

FDA records drug Class II recall D-0437-2024, published April 17, 2024 and initiated March 21, 2024. Recalling firm: Lupin Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 26,352 bottles; Lot: Lot #: A201064, Exp. Date March 2024. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent Drug

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Lupin Pharmaceuticals Inc.
Distributor
Nationwide within the United States
Lot
Lot #: A201064, Exp. Date March 2024
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Rifampin Capsules USP, 300mg, 30-count bottles, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202, Manufactured by: Lupin Limited Aurangabad 431 210 India, NDC 6818-0659-06 recalled?

Yes. FDA published recall D-0437-2024 on April 17, 2024. Reported hazard: Subpotent Drug

What should I do if I have this product?

Voluntary: Firm initiated · Letter